Register for OBR daily

Kantar Health Conference Sidebar

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

HALO $9.72 0.4900 +5.31%
CRIS $1.96 0.0790 +4.20%
CYTK $4.27 0.1100 +2.64%
ARGS $5.97 0.0900 +1.53%
PVCT $0.89 0.0090 +1.02%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

CBMG $19.25 -8.9200 -31.66%
VSTM $7.40 -0.7100 -8.75%
INO $10.12 -0.9100 -8.25%
EPZM $31.24 -2.3000 -6.86%
CNDO $1.50 -0.1100 -6.83%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | Next > | Last >>

Biogen Idec MS Drug is Approved by European Regulators

(Boston Globe) July 23, 2014 - Cambridge biotech Biogen Idec Inc. said Wednesday that it has received approval from the European Commission to sell Plegridy, an advanced new interferon drug to treat multiple sclerosis, in European countries.
read article (free registration required) 

Eagle Pharma's Drug to Treat Genetic Condition Gets U.S. Approval

(Reuters) July 23, 2014 - Eagle Pharmaceuticals Inc said the U.S. Food and Drug Administration approved its drug to treat an inherited life-threatening condition called malignant hyperthermia (MH).
read article 

A Dearth in Innovation for Key Drugs

(New York Times) July 22, 2014 - While researchers pursue high-cost remedies for rare ailments, development of broadly useful drugs like antibiotics is lagging.
read article 

Abuse of U.S. Generic-drug Rules Costs Consumers Billions, Report Says

(Reuters) July 23, 2014 - U.S. rules, aimed at ensuring prescription medicines are not misused, have been manipulated by brand-name drug companies to keep cheaper competition off the market, costing consumers billions of dollars, a report said on Wednesday.
read article 

Choosing Who Gets Costly Hepatitis C Cure Is Dilemma for Doctors

(Washington Post/Bloomberg) July 23, 2014 - Early this year, liver specialist Ken Flora and his colleagues sent letters to 1,300 patients announcing exciting news: powerful new drugs to cure the lethal hepatitis C virus were finally available.
read article (free registration required) 

The American Society of Hematology Honors Kanti R. Rai, MD, with 2014 Wallace H. Coulter Award for Lifetime Achievement in Hematology

(ASH) July 22, 2014 - The American Society of Hematology (ASH) will present the Society’s highest honor, the 2014 Wallace H. Coulter Award for Lifetime Achievement in Hematology, to Kanti R. Rai, MD, of the Hofstra North Shore-Long Island Jewish (LIJ) School of Medicine for his 50-year career combining landmark clinical leukemia research, steadfast commitment to education and mentoring, and exceptional patient care.
read press release 

Craig Mundie Joins RainTree Oncology Board of Directors

(CNBC) July 23, 2014 - RT Oncology Services Corporation today announced that Craig Mundie has agreed to join its board of directors.
read article 

WellStar Hires New Lead for Cancer Program

( July 22, 2014 - Joel Helmke joins as corporate vice president of oncology services from MD Anderson.
read article 

The Curious Case of the Exceptional Responder

(AACR/Cancer Research Catalyst blog) July 21, 2014 - For decades, experimental cancer drugs that did not provide measurable benefit to a significant number of patients in a clinical trial were considered “failed,” and further efforts to develop the drug for that use were shelved.
read article 

CancerRx App Looks at Clinical Trials & Treatments That Target the Molecular Profile for Certain Cancers

( July 22, 2014 - CancerRx could be a useful app in the oncology world if one was looking for a quick list of possible therapy options targeting molecular profiles of certain tumors. This app currently includes only lung cancer, metastatic breast cancer, melanoma and colorectal cancer with plans to expand the scope at a later date.
read article 

Foundation Medicine Partners with the Addario Lung Cancer Medical Institute for Innovative Prospective Study Linking the Genomic Drivers of Lung Cancer in Young Adults with Treatment Options

(4-traders) July 23, 2014 - Newly launched international study aims to better inform treatment options for lung cancer in a unique, underserved population.
read article 

Turkish Man Pleads Guilty to Smuggling Fake Cancer Drugs Into U.S.

(Wall Street Journal) July 22, 2014 - A Turkish man pleaded guilty in U.S. federal court to smuggling counterfeit and misbranded cancer drugs into the U.S., the Justice Department said Tuesday.
read article (paid subscription required) 

100 Hospitals and Health Systems With Great Oncology Programs 2014

(Becker's Hospital Review) July 22, 2014 - Becker's Hospital Review has named the following hospitals to the 2014 edition of "100 Hospitals and Health Systems With Great Oncology Programs." These hospitals are leading the way in terms of quality patient care, cancer outcomes and research.
read article 

Ganymed Completes Recruitment for Gastroesophageal Cancer Drug Trial

(Drug Discovery & Development) July 22, 2014 - Ganymed Pharmaceuticals AG announced that it has completed recruitment of 210 patients for its Phase 2 FAST clinical trial to evaluate the combination of IMAB362 and chemotherapy as first-line therapy in patients with gastroesophageal cancer (GEC).
read press release 

Sarah Cannon Research UK and BioMarin Collaborate on EMBRACA Clinical Study in Hereditary Breast Cancer With BRCA Mutation

(Yahoo! Finance) July 23, 2014 - BioMarin Pharmaceutical Inc. and Sarah Cannon Research UK today announced a collaboration to enroll patients in an ongoing Phase 3 clinical trial of its PARP inhibitor, BMN 673, for the treatment of hereditary breast cancer with a BRCA mutation.
read article 

Lacking Trust in One's Doctor Affects Health of Emotionally Vulnerable Cancer Patients

(Center for Advancing Health/Health Behavior News Service) July 22, 2014 - A new study indicates that the physical and mental well-being of people with cancer may be affected by how they feel about their relationship with their physician and by differences in attachment styles (how they rely and depend on others).
read press release 

Comprehensive Rehab Programs Beneficial in Advanced Cancer

(Medscape Medical News) July 23, 2014 - A program that combines nutritional counseling, exercise, and symptom control can improve the symptomatic course of advanced cancer.
read article (free registration required) 

Unique Study Focuses on Combined Treatment Approach for Locally Advanced Pancreatic Cancer

(Cedars-Sinai) July 21, 2014 – Investigators at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute are developing a novel, multistep investigational treatment for one of the most complex and difficult-to-treat forms of the disease, locally advanced pancreatic cancer.
read press release 

Alternative Sunitinib Treatment Schedules for mRCC May be Worth the Switch

(medwireNews) July 22, 2014 - Some patients with metastatic renal cell carcinoma (mRCC) who are switched from a traditional sunitinib treatment schedule to an alternative schedule fare better on survival measures and suffer fewer adverse events, a Japanese study has found.
read article 

Emesis Combo Quells CINV in Three Trials

(MedPage Today) July 22, 2014 - A single-dose antiemetic regimen provided superior control of chemotherapy-induced nausea and vomiting as compared with a standard multidose regimen, according to results from multiple trials.
read article (free registration required) 

Inovio Pharma's Drug to Treat Cervical Lesions Meets Trial Goal

(Reuters) July 23, 2014 - Inovio Pharmaceuticals Inc said its drug to treat abnormal growth of pre-cancerous cells on the surface of the cervix met its main goal in a mid-stage trial.
read article 

Puma Biotechnology Soars on Breast Cancer Drug Results

(Bloomberg) July 22, 2014 - Puma Biotechnology Inc. almost tripled in extended trading after the company said a clinical trial of its experimental drug blocked the return of breast cancer in women with a type of early-stage disease.
read article 

FDA Approves Zydelig for Three Types of Blood Cancers

( July 23, 2014 - The U.S. Food and Drug Administration today approved Zydelig (idelalisib) to treat patients with three types of blood cancers.
read press release 

Puma Says Cancer Drug Meets Trial Goal, Shares Soar

(Reuters) July 22, 2014 - Puma Biotechnology Inc said its experimental breast cancer drug met its main goal in a late-stage trial.
read article 

Cancer Drugs Yervoy, Xtandi Get NICE Thumbs Up

(PharmaTimes [UK]) July 23, 2014 - Cost regulators for the National Health Service in England and Wales have this morning issued guidance recommending the use of Bristol-Myers Squibb's Yervoy (ipilimumab) for skin cancer and Astellas' Xtandi (enzalutamide) for prostate cancer.
read article